BIOMAT Database Logo BIOMAT Database Logo

In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate. 1997

S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review.
February 1998, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine.
January 1996, AIDS (London, England),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
January 2002, Antiviral research,
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
January 1998, AIDS (London, England),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
January 1996, Biotherapy (Dordrecht, Netherlands),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.
February 1999, AIDS (London, England),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
December 1996, AIDS (London, England),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
June 1996, AIDS (London, England),
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
January 1999, Antiviral therapy,
S Rusconi, and M P De Pasquale, and L Milazzo, and E Bulgheroni, and P Citterio, and S Kurtagic, and A d'Arminio-Monforte, and M Galli
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
January 2000, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!